Phase II study of recombinant antitumor and antivirus protein injection compared with placebo in metastatic colorectal cancer after failure of standard treatment
R Jia, Y Wang, XY Mao, SS Li, N Xu, JP Xiong… - The …, 2015 - academic.oup.com
Abstract Lessons Learned Novaferon showed moderate efficacy and was well-tolerated in
patients with metastatic colorectal cancer (mCRC), especially with the 20 μg injected 3 times …
patients with metastatic colorectal cancer (mCRC), especially with the 20 μg injected 3 times …
Phase II Study of Recombinant Antitumor and Antivirus Protein Injection Compared With Placebo in Metastatic Colorectal Cancer After Failure of Standard Treatment.
R Jia, Y Wang, XY Mao, SS Li, N Xu, JP Xiong… - The …, 2015 - europepmc.org
Background To observe the efficacy, safety, and optimal dosage of recombinant antitumor
and antivirus protein (Novaferon) in treating patients with metastatic colorectal cancer …
and antivirus protein (Novaferon) in treating patients with metastatic colorectal cancer …
[HTML][HTML] Phase II Study of Recombinant Antitumor and Antivirus Protein Injection Compared With Placebo in Metastatic Colorectal Cancer After Failure of Standard …
R Jia, Y Wang, XY Mao, SS Li, N Xu, JP Xiong… - The …, 2015 - ncbi.nlm.nih.gov
Background. To observe the efficacy, safety, and optimal dosage of recombinant antitumor
and antivirus protein (Novaferon) in treating patients with metastatic colorectal cancer …
and antivirus protein (Novaferon) in treating patients with metastatic colorectal cancer …
[PDF][PDF] Phase II Study of Recombinant Antitumor and Antivirus Protein Injection Compared With Placebo in Metastatic Colorectal Cancer After Failure of Standard …
R Jia, Y Wang, XY Mao, SS Li, N Xu, JP Xiong… - The …, 2015 - Wiley Online Library
Lessons Learned Novaferon showed moderate efficacy and was well‐tolerated in patients
with metastatic colorectal cancer (mCRC), especially with the 20 μg injected 3 times a week …
with metastatic colorectal cancer (mCRC), especially with the 20 μg injected 3 times a week …
Phase II Study of Recombinant Antitumor and Antivirus Protein Injection Compared With Placebo in Metastatic Colorectal Cancer After Failure of Standard Treatment
R Jia, Y Wang, XY Mao, SS Li, N Xu… - The …, 2015 - pubmed.ncbi.nlm.nih.gov
Lessons learned Novaferon showed moderate efficacy and was well-tolerated in patients
with metastatic colorectal cancer (mCRC), especially with the 20 μg injected 3 times a week …
with metastatic colorectal cancer (mCRC), especially with the 20 μg injected 3 times a week …
Phase II Study of Recombinant Antitumor and Antivirus Protein Injection Compared With Placebo in Metastatic Colorectal Cancer After Failure of Standard Treatment
J Ru, W Yan, M Xiao-Yang, L Shan-Shan, X Nong… - m.marthaarifin.com
To observe the efficacy, safety, and optimal dosage of recombinant antitumor and antivirus
protein (Novaferon) in treating patients with metastatic colorectal cancer (mCRC) who failed …
protein (Novaferon) in treating patients with metastatic colorectal cancer (mCRC) who failed …
Phase II Study of Recombinant Antitumor and Antivirus Protein Injection Compared With Placebo in Metastatic Colorectal Cancer After Failure of Standard Treatment.
R Jia, Y Wang, XY Mao, SS Li, N Xu, JP Xiong… - …, 2015 - search.ebscohost.com
Background. To observe the efficacy, safety, and optimal dosage of recombinant antitumor
and antivirus protein (Novaferon) in treating patients with metastatic colorectal cancer …
and antivirus protein (Novaferon) in treating patients with metastatic colorectal cancer …
Phase II Study of Recombinant Antitumor and Antivirus Protein Injection Compared With Placebo in Metastatic Colorectal Cancer After Failure of Standard Treatment.
R Jia, Y Wang, XY Mao, SS Li, N Xu, JP Xiong… - The …, 2015 - europepmc.org
Background To observe the efficacy, safety, and optimal dosage of recombinant antitumor
and antivirus protein (Novaferon) in treating patients with metastatic colorectal cancer …
and antivirus protein (Novaferon) in treating patients with metastatic colorectal cancer …